Active	Status	Sponsor type	Region	Phase	Filter
4 Active 3 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Petrini, Mario
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma	Recruiting	3	870	Europe	R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)	Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum	Mantle Cell Lymphoma	05/21	05/26
GITMO-PHYLOS, NCT03270748: Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies	Completed	2	78	Europe	GvHD prophylaxis	Gruppo Italiano Trapianto di Midollo Osseo	Myeloid Malignancies	11/22	11/22
NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance	Recruiting	2	90	Europe	Ibrutinib, IMBRUVICA (commercial name)	Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.	DLBCL	06/24	07/27
FIL_Copa-RB, NCT04433182 / 2019-004898-63: Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma	Active, not recruiting	2	37	Europe	Copanlisib, ALIQOPA	Fondazione Italiana Linfomi - ETS	Diffuse Large B-cell Lymphoma	12/24	12/24
Pelosini, Matteo
No trials found